With pharmaceutical GLP-1 drugs like semaglutide in high demand, Metamorphx offers a plant-based alternative designed to ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

SHOPPING: If you're ready to meet your weight goals, turn to Hims for personalized weight loss treatments that are ...

Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...